Literature DB >> 20717853

Frontotemporal dementia and primary progressive aphasia: an update.

Howard S Kirshner1.   

Abstract

Frontotemporal dementias are syndromes of progressive dysfunction of the frontal and/or temporal lobes, either unilaterally or bilaterally. These syndromes were described clinically under the terms "primary progressive aphasia" in the United States and "frontotemporal dementia" in Europe and the United Kingdom. They are diagnosed by the clinical features of a frontal lobe neurobehavioral syndrome, or a language and cognitive deterioration. In recent years, molecular genetic findings in these syndromes, especially the tau and progranulin mutations on chromosome 17, have provided a molecular and genetic foundation for the understanding of frontotemporal dementia. These disorders are distinct from Alzheimer's disease but have some overlap with the syndrome of corticobasal degeneration, and with motor neuron disease. Treatments remain very limited, mainly involving therapy for the mood and behavioral symptoms, but advances in the molecular and genetic understanding of these conditions will hopefully lead to more specific therapies in the future.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20717853     DOI: 10.1007/s11910-010-0145-z

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  83 in total

1.  Apolipoprotein E genotypes in primary progressive aphasia.

Authors:  M M Mesulam; N Johnson; Z Grujic; S Weintraub
Journal:  Neurology       Date:  1997-07       Impact factor: 9.910

2.  Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors.

Authors:  J R Swartz; B L Miller; I M Lesser; A L Darby
Journal:  J Clin Psychiatry       Date:  1997-05       Impact factor: 4.384

3.  Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial.

Authors:  J B Deakin; S Rahman; P J Nestor; J R Hodges; B J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2003-12-10       Impact factor: 4.530

4.  Slowly progressive aphasia without generalized dementia.

Authors:  M M Mesulam
Journal:  Ann Neurol       Date:  1982-06       Impact factor: 10.422

5.  Emergence of artistic talent in frontotemporal dementia.

Authors:  B L Miller; J Cummings; F Mishkin; K Boone; F Prince; M Ponton; C Cotman
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

6.  Progressive aphasia in a patient with Pick's disease: a neuropsychological, radiologic, and anatomic study.

Authors:  N R Graff-Radford; A R Damasio; B T Hyman; M N Hart; D Tranel; H Damasio; G W Van Hoesen; K Rezai
Journal:  Neurology       Date:  1990-04       Impact factor: 9.910

7.  Progressive aphasia without dementia: two cases with focal spongiform degeneration.

Authors:  H S Kirshner; O Tanridag; L Thurman; W O Whetsell
Journal:  Ann Neurol       Date:  1987-10       Impact factor: 10.422

8.  Familial aggregation in frontotemporal dementia.

Authors:  M Stevens; C M van Duijn; W Kamphorst; P de Knijff; P Heutink; W A van Gool; P Scheltens; R Ravid; B A Oostra; M F Niermeijer; J C van Swieten
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

9.  Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET study.

Authors:  J Diehl; T Grimmer; A Drzezga; M Riemenschneider; H Förstl; A Kurz
Journal:  Neurobiol Aging       Date:  2004-09       Impact factor: 4.673

10.  Progressive Nonfluent Aphasia: Language, Cognitive, and PET Measures Contrasted with Probable Alzheimer's Disease.

Authors:  M Grossman; J Mickanin; K Onishi; E Hughes; M D'Esposito; X S Ding; A Alavi; M Reivich
Journal:  J Cogn Neurosci       Date:  1996       Impact factor: 3.225

View more
  7 in total

Review 1.  Primary progressive aphasia and Alzheimer's disease: brief history, recent evidence.

Authors:  Howard S Kirshner
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

2.  Genetics of Frontotemporal Dementia.

Authors:  F W Rohlfing; R K Tu
Journal:  AJNR Am J Neuroradiol       Date:  2016-09-29       Impact factor: 3.825

3.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

4.  Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia.

Authors:  Basar Cenik; Chantelle F Sephton; Colleen M Dewey; Xunde Xian; Shuguang Wei; Kimberley Yu; Wenze Niu; Giovanni Coppola; Sarah E Coughlin; Suzee E Lee; Daniel R Dries; Sandra Almeida; Daniel H Geschwind; Fen-Biao Gao; Bruce L Miller; Robert V Farese; Bruce A Posner; Gang Yu; Joachim Herz
Journal:  J Biol Chem       Date:  2011-03-23       Impact factor: 5.157

5.  Longitudinal Imaging and Deterioration in Word Comprehension in Primary Progressive Aphasia: Potential Clinical Significance.

Authors:  Andreia V Faria; Rajani Sebastian; Melissa Newhart; Susumu Mori; Argye E Hillis
Journal:  Aphasiology       Date:  2014-08       Impact factor: 2.773

6.  Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

Authors:  Jean-Paul Soucy; Robert Bartha; Christian Bocti; Michael Borrie; Amer M Burhan; Robert Laforce; Pedro Rosa-Neto
Journal:  Alzheimers Res Ther       Date:  2013-07-08       Impact factor: 6.982

7.  Prevalence of frontotemporal dementia in community-based studies in Latin America: a systematic review.

Authors:  Nilton Custodio; Eder Herrera-Perez; David Lira; Rosa Montesinos; Liliana Bendezu
Journal:  Dement Neuropsychol       Date:  2013 Jan-Mar
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.